James Paul Lang
CIK: 0001703090
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jun 9, 2026OPRX
OptimizeRx Corp
Award(A)Direct34.5K shares- - May 5, 2026HALO
HALOZYME THERAPEUTICS, INC.
Award(A)Direct3.8K shares- - Jan 5, 2026BIVI
BIOVIE INC.
Award(A)DirectStock Option (right to buy)
330.5K shares- - Jan 5, 2026BIVI
BIOVIE INC.
Award(A)DirectStock Option (right to buy)
90K shares- - Jan 2, 2026HALO
HALOZYME THERAPEUTICS, INC.
Award(A)Direct889 shares- - Jun 11, 2025OPRX
OptimizeRx Corp
Award(A)Direct9.9K shares- - Mar 14, 2025OPRX
OptimizeRx Corp
Purchase(P)Direct321.4K shares at avg. $7.60$2.4M - Dec 20, 2024BIVI
BIOVIE INC.
Award(A)DirectStock Option (right to buy)
22.7K shares- - Nov 20, 2024BIVI
BIOVIE INC.
Award(A)DirectStock Option (right to buy)
61.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 9, 2026 |  OPRX OptimizeRx Corp | Award(A) | 34,517 | - | $0 | Direct |
| May 5, 2026 |  HALO HALOZYME THERAPEUTICS, INC. | Award(A) | 3,796 | - | $0 | Direct |
| Jan 5, 2026 |  BIVI BIOVIE INC. | Award(A) Stock Option (right to buy) | 330,500 | - | - | Direct |
| Jan 5, 2026 | BIVI BIOVIE INC. | Award(A) Stock Option (right to buy) | 90,000 | - | - | Direct |
| Jan 2, 2026 | HALO HALOZYME THERAPEUTICS, INC. | Award(A) | 889 | - | $0 | Direct |
| Jun 11, 2025 | OPRX OptimizeRx Corp | Award(A) | 9,868 | - | - | Direct |
| Mar 14, 2025 | OPRX OptimizeRx Corp | Purchase(P) | 321,408 | $7.60 | $2,443,761 | Direct |
| Dec 20, 2024 | BIVI BIOVIE INC. | Award(A) Stock Option (right to buy) | 22,690 | - | - | Direct |
| Nov 20, 2024 | BIVI BIOVIE INC. | Award(A) Stock Option (right to buy) | 61,600 | - | - | Direct |
1-9 of 9 transactions
About Lang James Paul
Lang James Paul (SEC CIK 0001703090) files insider reports with the SEC as Director of OptimizeRx Corp (OPRX), Director of HALOZYME THERAPEUTICS, INC. (HALO) and Director of BIOVIE INC. (BIVI).
Signal8 holds 8 ownership filings by Lang James Paul (1 Form 3, 7 Form 4), filed between Jan 7, 2025 and Jun 10, 2026. Those filings report 9 transactions, from Nov 20, 2024 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lang James Paul's filings is in WALTHAM, MA.
Recent filings by Lang James Paul
- Jun 9, 2026: Grant or award of OPRX shares (Form 4, code A).
- May 5, 2026: Grant or award of HALO shares (Form 4, code A).
- Jan 5, 2026: Grants or awards of BIVI derivative securities (2 lines, Form 4, code A).
- Jan 2, 2026: Grant or award of HALO shares (Form 4, code A).
- Jun 11, 2025: Grant or award of OPRX shares (Form 4, code A).
Other insiders filing for OptimizeRx Corp (OPRX)
- D'Silva Andrew J., Chief Business Officer
- Silvestro Stephen L, Chief Executive Officer
- Merrell Brendan W., CHIEF OPERATING OFFICER
- Odence-Ford Marion, Chief Legal & Admin Officer
- Stelmakh Edward, Chief Finance & Strat Officer
- KLEMA CATHY, Director